UK Markets close in 4 hrs 30 mins
  • FTSE 100

    7,053.72
    +144.96 (+2.10%)
     
  • FTSE 250

    17,765.06
    +480.18 (+2.78%)
     
  • AIM

    814.75
    +6.02 (+0.74%)
     
  • GBP/EUR

    1.1470
    -0.0046 (-0.40%)
     
  • GBP/USD

    1.1346
    +0.0027 (+0.2383%)
     
  • BTC-GBP

    17,604.38
    +592.75 (+3.48%)
     
  • CMC Crypto 200

    454.02
    +18.66 (+4.29%)
     
  • S&P 500

    3,678.43
    +92.81 (+2.59%)
     
  • DOW

    29,490.89
    +765.38 (+2.66%)
     
  • CRUDE OIL

    84.17
    +0.54 (+0.65%)
     
  • GOLD FUTURES

    1,718.50
    +16.50 (+0.97%)
     
  • NIKKEI 225

    26,992.21
    +776.42 (+2.96%)
     
  • HANG SENG

    17,079.51
    -143.29 (-0.83%)
     
  • DAX

    12,595.34
    +385.86 (+3.16%)
     
  • CAC 40

    6,000.13
    +205.98 (+3.55%)
     

Baader Bank initiates research coverage on Xlife Sciences

·3-min read

Xlife Sciences AG / Key word(s): Miscellaneous
Baader Bank initiates research coverage on Xlife Sciences
15.09.2022 / 07:00 CET/CEST

Baader Bank, one of the leading European partners for investment and banking services, has initiated its research coverage on Xlife Sciences (SIX: XLS). The initial analyst report published today starts with a “Buy” rating and a target price of CHF 69.80.

The report confirms Xlife Sciences' position as an emerging life sciences incubator, offering investors an attractive opportunity to invest in a number of promising and diverse life sciences projects under one umbrella. The broad diversified portfolio targets promising and growing therapeutic areas such as oncology, neurological diseases and advanced treatments such as DNA repairing and artificial intelligence. The report also mentions the highly experienced founding and management team that already a track record of successful transactions over the past two years, thus driving the company's commercialisation initiatives.

An excerpt of Baader Bank’s analyst report can be viewed and downloaded on Xlife Science’s website at https://www.xlifesciences.ch/en/news-and-key-figures.

Oliver R. Baumann, CEO of Xlife Sciences, commented: “We are pleased about the research coverage of Xlife Sciences AG by Baader Bank. This provides our investors with a further independent insight. We look forward to explaining this further with them in personal discussions.”

Financial calendar

Zurich Capital Markets Conference 2022            15 September 2022

Baader Investment Conference 2022                  19-23 September 2022

Investora 2022 Conference Zurich                       21-22 September 2022

Semi-Annual Report 2022                                    28 September 2022

 

Contact

Information for journalists: IRF Reputation AG, Valentin Handschin, handschin@irf-reputation.ch

Information for investors: Xlife Sciences AG, Dennis Lennartz, dennis.lennartz@xlifesciences.ch

Xlife Sciences AG

 

Talacker 35

8001 Zürich

Telefon: 0041 44 385 84 60

E-Mail: info@xlifesciences.ch

Internet: www.xlifesciences.ch

ISIN: CH0461929603

WKN: A2PK6Z

Börsen: SIX Swiss Exchange

About Xlife Sciences AG (SIX: XLS)

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch

Disclaimer

Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.


End of Media Release

Language:

English

Company:

Xlife Sciences AG

Talacker 35

8001 Zürich

Switzerland

Phone:

+41 44 385 84 60

E-mail:

info@xlifesciences.ch

Internet:

www.xlifesciences.ch

ISIN:

CH0461929603

Valor:

A2PK6Z

Listed:

SIX Swiss Exchange

EQS News ID:

1442857


 

End of News

EQS News Service

show this
show this